irAEs according to category and grade
| Category | Patients, n (%) | Grade 1–2 | Grade 3–4 | Weeks to onset, median (range) |
| Total | ||||
| Any | 186 (39.5) | 144 (30.6) | 42 (8.9) | 21 (0.3–356) |
| Dermatological | ||||
| Rash+pruritus | 36 (7.7) | 31 (6.6) | 5 (1.1) | 7 (2–100) |
| Mucositis | 2 (0.4) | 1 (0.2) | 1 (0.2) | 23 (21–25) |
| Pulmonary | ||||
| Pneumonitis | 14 (3.0) | 13 (2.8) | 1 (0.2) | 19 (4–100) |
| Endocrine | ||||
| Hypothyroid | 42 (8.9) | 42 (8.9) | 0 | 13 (1–154) |
| Adrenal insufficiency | 1 (0.2) | 1 (0.2) | 0 | 10 |
| Gastroentelorogical | ||||
| Diarrhea/colitis | 35 (7.4) | 17 (3.6) | 18 (3.8) | 17 (2–253) |
| Hepatobiliary | ||||
| Transaminitis | 32 (6.8) | 20 (4.3) | 12 (2.6) | 12 (2–81) |
| Rheumatological/musculoskeletal | ||||
| Joint pain | 12 (2.6) | 11 (2.3) | 1 (0.2) | 9 (1–67) |
| Myalgia | 5 (1.1) | 4 (0.9) | 1 (0.2) | 25 (2–64) |
| Others | ||||
| Nephritis | 3 (0.6) | 2 (0.4) | 1 (0.2) | 17 (1–64) |
| Pancreatitis | 2 (0.4) | 0 | 2 (0.4) | 21 (16–25) |
| Pericarditis | 1 (0.2) | 1 (0.2) | 0 | 8 |
| Uveitis | 1 (0.2) | 1 (0.2) | 0 | 56 |
irAEs, immune-related adverse events.